ASX Share rice
Fri 14 Aug 2020 - 12:44:pm (Sydney)

BNO Share Price

BIONOMICS LIMITEDBNOPharmaceuticals, Biotechnology & Life Sciences

BNO Company Information

Name:

Bionomics Limited

Sector:

Healthcare

Industry:

Biotechnology

GIC Industry:

Biotechnology

GIC Sub Industry:

Biotechnology

Address:

31 Dalgleish Street Thebarton Australia 5031

Phone:

61 8 8354 6100

Exec. Chairman:

Dr. Errol B. De Souza

Acting Chief Financial Officer:

Mr. Adrian Hinton

Legal Counsel & Company Sec.:

Mr. Jack Moschakis B.E., BEc, DipLaw(BAB), GDipBA, FCIS

Consultant Chief Medical Officer of Clinical Neuroscience:

Prof. Paul Rolan

Company Overview:

Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia, France, and the United States. It operates through Drug Discovery and Development, and Contract Services segments. The company's lead product candidate includes BNC210, a negative allosteric modulator, which is in various clinical trials for the treatment of anxiety, panic, agitation, and post-traumatic stress disorder. It also develops BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that targets cancer stem cells; and BNC105, a vascular disrupting agent for the treatment of cancer, as well as disrupts the blood vessels that nourish tumors in cancer treatment. In addition, the company offers contract research services. Bionomics Limited has a strategic partnership with Merck & Co., Inc. The company was incorporated in 1996 and is based in Thebarton, Australia.

BNO Share Price Information

Shares Issued:

626.19M

Market Capitalisation:

$54.48M

Revenue (TTM):

$10.15M

Revenue Per Share (TTM):

$0.02

Earnings per Share:

$-0.02

Profit Margin:

-0.4819

Operating Margin (TTM):

$-0.15

Return On Assets (TTM):

$-0.02

Return On Equity (TTM):

$-0.27

Quarterly Revenue Growth (YOY):

-0.398

Gross Profit(TTM):

$2.38M

Diluted Earnings Per Share (TTM):

$-0.01

BNO CashFlow Statement

CashFlow Date:

2019-06-30

Investments:

$197.65K

Change To Liabilities:

$-1,654,410

Total Cashflow From Investing Activities:

$197.65K

Net Borrowings:

$-5,327,426

Net Income:

$-9,669,115

Total Cash From Operating Activities:

$-15,581,904

Depreciation:

$1.71M

Other Cashflow From Investing Activities:

$282.65K

Change To Inventory:

$-152,316

Change To Account Receivables:

$-147,310

Sale Purchase Of Stock:

$-420,369

Capital Expenditures:

$98.93K

BNO Income Statement

Income Date:

2019-06-30

Income Before Tax:

$-9,905,851

Net Income:

$-9,669,115

Gross Profit:

$3.82M

Operating Income:

$-15,359,130

Interest Expense:

$2.36M

Income Tax Expense:

$-236,736

Total Revenue:

$3.82M

Total Operating Expenses:

$19.18M

Cost Of Revenue:

$8.98M

BNO Balance Sheet

Balance Sheet Date:

2019-06-30

Intangible Assets:

$12.87M

Total Liabilities:

$35.96M

Total Stockholder Equity:

$17.70M

Other Current Liabilities:

$262.90K

Total Assets:

$53.66M

Common Stock:

$144.94M

Other Current Assets:

$7.84M

Retained Earnings:

$-140,865,629

Other Liabilities:

$13.51M

Good Will:

$12.76M

Other Assets:

$384K

Cash:

$13.99M

Total Current Liabilities:

$13.80M

Short-Term Debt:

$8.45M

Property - Plant & Equipment:

$2.51M

Net Tangible Assets:

$-7,937,466

Long-Term Investments:

$384K

Total Current Assets:

$25.13M

Long-Term Debt:

$8.65M

Net Receivables:

$816.75K

Short-Term Investments:

$28.53M

Inventory:

$664.54K

Accounts Payable:

$1.20M

Non Currrent Assets (Other):

$28.53M

Short-Term Investments:

$28.53

Non Current Liabilities (Other):

$9.80M

Non Current Liabilities Total:

$22.16M

BNO Share Price History

BNO News

02 Jun, 2020
Bionomics A$20-A$22 million recapitalisation led by Apeiron Investment Group
31 Mar, 2020
Published preclinical findings for Bionomics Limited's BNC375 explore the potential of this novel molecule to improve cognitive impairment.
20 Mar, 2020
We're definitely into long term investing, but some companies are simply bad investments over any time frame. We...
11 Dec, 2019
Bionomics Limited has accepted offer from Domain Therapeutics for subsidiaries Neurofit SAS and PC SAS (Prestwick Chemical) in France.
04 Nov, 2019
Bionomics Limited (ASX:BNO, OTCQX:BNOEF), a global, clinical stage biopharmaceutical company discovering and developing a pipeline of novel drug candidates targeting ion channels, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the BNC210 development program for the treatment of Post-Traumatic Stress Disorder (PTSD) and other trauma-related and stressor-related disorders.
23 Sep, 2019
If you own shares in Bionomics Limited (ASX:BNO) then it's worth thinking about how it contributes to the volatility...